BioCryst Pharmaceuticals Inc. (BCRX)
BCRX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/882796/000162828026012240/0001628280-26-012240-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BCRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 1994 |
| SEC CIK | 0000882796 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $874.8M |
| Net income | $263.9M |
| Operating income | $341.0M |
| Net margin | 30.2% |
| Operating margin | 39.0% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $89.7M |
| Total assets | $514.2M |
| P/E (computed) | 7.8× |
| P/S (computed) | 2.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-12-18 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report FORM 8-K | 8-K | 2026-08-05 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.2% |
| 1 month | -1.3% |
| 3 months | -11.6% |
| Year to date | +3.2% |
| 1 year | +14.3% |
| From 52-week high | -27.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VCEL | Vericel Corporation | $40.30 | -0.79% | $2.1B |
| RXRX | Recursion Pharmaceuticals Inc. | $3.83 | -4.36% | $2.1B |
| ALVO | Alvotech | $5.38 | -2.18% | $2.1B |
| NVAX | Novavax Inc. | $12.82 | +1.26% | $2.1B |
| ADMA | ADMA Biologics Inc | $10.31 | +1.28% | $2.3B |
| MESO | Mesoblast Limited | $13.89 | -2.63% | $1.8B |
| VIR | Vir Biotechnology Inc. | $10.61 | -6.11% | $1.8B |
| BEAM | Beam Therapeutics Inc. | $24.43 | -2.79% | $2.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier